Recent scrutiny of Neuralink’s animal testing practices has reignited debates about ethics in cutting-edge medical research. Despite no regulatory actions following a 2023 FDA inspection, concerns about animal welfare and invasive testing methods remain. This highlights the bio-health sector’s challenge: balancing rapid innovation with ethical responsibility.
Advancements in organ-on-chip technology and AI modeling offer promising alternatives, paving the way for more humane and precise research methods. The Neuralink case serves as a wake-up call, urging us to rethink the role of animals in science and embrace ethical innovation.
